Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Enrichment & Purging of Stem Cells in Non-Hodgkin's Lymphoma

This study has been completed.
National Institutes of Health (NIH)
Information provided by (Responsible Party):
Stanford University Identifier:
First received: September 13, 2005
Last updated: May 10, 2012
Last verified: May 2012
To evaluate the role of purging the hematopoietic cell graft on outcomes for non-Hodgkin's Lymphoma.

Condition Intervention
Lymphoma, Non-Hodgkin
Procedure: high dose chemo then auto hematopoietic cell transplant

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Enrichment and Purging of Stem Cells in the Treatment of Non-Hodgkin's Lymphoma

Resource links provided by NLM:

Further study details as provided by Stanford University:

Primary Outcome Measures:
  • PCR positivity in peripheral blood cell collections after cyclophosphamide [ Time Frame: unknown ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Enrichment of hematopoietic stem cells [ Time Frame: unknown ] [ Designated as safety issue: No ]

Enrollment: 97
Study Start Date: October 2003
Study Completion Date: February 2010
Primary Completion Date: March 2007 (Final data collection date for primary outcome measure)
Detailed Description:
To study the use of peripheral blood stem cells which have been treated in an effort to remove tumor cells. The researchers hope to learn whether or not this will be more effective in removing the tumor cells as compared to other methods of purging (the removal of cancer cells).

Ages Eligible for Study:   up to 75 Years   (Child, Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:- relapsed NHL

Exclusion Criteria:- liver dysfunction

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00186355

United States, California
Stanford University School of Medicine
Stanford, California, United States, 94305
Sponsors and Collaborators
Stanford University
National Institutes of Health (NIH)
Principal Investigator: Robert S Negrin Stanford University
  More Information

Responsible Party: Stanford University Identifier: NCT00186355     History of Changes
Other Study ID Numbers: BMT4IJ  77063  12170 
Study First Received: September 13, 2005
Last Updated: May 10, 2012
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Lymphoma, Non-Hodgkin
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases processed this record on October 21, 2016